Name | Cantuzumab ravtansine |
---|
Description | Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2]. |
---|---|
Related Catalog | |
In Vitro | Cantuzumab ravtansine(huC242-DM4;5 天)在 CanAg 阳性 SNU16 胃癌细胞中表现出细胞毒性作用[2]。 |
In Vivo | Cantuzumab ravtansine(huC242-DM4;静脉注射;3.4 mg/kg;单剂量)可使携带 N87 人胃肿瘤异种移植物的 SCID 小鼠的肿瘤完全消退,在低于 2 mg/kg 的剂量下观察到显着的肿瘤消退 [1]。 Cantuzumab ravtansine (huC242-DM4) 在携带人结肠肿瘤异种移植物 HT29 和 COLO 205 细胞的小鼠中也有疗效,且无毒副作用[1]。 |
References |
No Any Chemical & Physical Properties |